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Ecotropic Virus Integration site 12 (Evi12) is a common virus insertion site (cVIS) in retrovirally induced murine models of leukemia and
lymphoma, suggesting an important role for this locus in these hematopoietic disorders. Evi12 is located near the promoter of the ER chaperone
protein and Hsp90 family member Grp94. Here we show that viral insertion in Evi12 results in the expression of aberrant Grp94 transcripts in Cas-
Br-MuLV as well as in AKXD induced hematopoietic tumors, demonstrating that Grp94 is a common viral target gene. While most transcripts
encode for truncated forms of Grp94, transcripts containing viral gag sequences were detected in the leukemia cell line NFS107. Interestingly, these
fusion transcripts encode for myristylated viral–Grp94 fusion proteins that localize to the plasma membrane. Combined with recent evidence that
myristylated forms of Hsp90 transform cells, our data suggest that myristylation of target genes may be an important mechanism in retrovirally
mediated oncogenesis. Since retroviral insertion in Evi12 also affects the expression of a recently identified novel gene Grp94 neighboring
nucleotidase (Gnn), located at the other side of Evi12, it appears that proviral insertion can lead to deregulation of two genes present in the same
locus.
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The identification of common virus integration sites (VISs)
in retrovirally induced leukemias is a valid tool for identifying
novel transforming genes in human disease (Erkeland et al.,
2006). Proviral insertion may result in transcriptional upregu-
lation or inactivation of the target gene, or in generation of
truncated proteins (Jonkers and Berns, 1996). A small area
upstream of the Grp94 gene on mouse chromosome 10 is a
frequent target in retrovirally induced leukemia and lym-
phoma. This VIS, designated Evi12, was identified in the
tumor cell line NFS107 using a RT-PCR based screen for
novel virus flanking fragments. Using locus-specific primers,
viral insertions in Evi12 were found in both orientations in a
high percentage of the Cas-Br-MuLV induced tumors (Valk et⁎ Corresponding author. Fax: +31 10 4089470.
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doi:10.1016/j.virol.2007.04.026al., 1999; Joosten et al., 2000). Although these insertions were
located near the Grp94 promoter, no increase in Grp94 mRNA
or protein expression was observed between Evi12-positive and
-negative tumors (Valk et al., 1999). We did demonstrate
increased RNA and protein expression of the novel gene Grp94
neighboring nucleotidase (Gnn) in NFS107, strongly suggesting
that this gene is deregulated due to the viral insertion in Evi12
(van den Akker et al., 2005). Recently, Suzuki and colleagues
identified 3 novel Evi12 virus integration sites in T- and B-cell
leukemias in AKXD mice (Akagi et al., 2004; Suzuki et al.,
2002). Since these integrations and the one in NFS107, that were
all picked up by PCR without the use of gene-specific primers,
are in the same orientation as Grp94 transcription, we re-
evaluated the possibility that not only Gnn but also Grp94 is a
target of Evi12 using RT-PCR. The results presented here show
that (1) Grp94 is a target of the viral integration in Evi12, (2)
viral insertion can thus lead to the deregulation of more than one
gene and (3) viral insertion may result in N-myristylation of
cellular target genes.
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Identification of viral–Grp94 fusion products in the Evi12
containing cell line NFS107
The viral insertions in Evi12 are located in a 1.7-kb region
that is 500 bp upstream of the first exon of Grp94 on mouse
chromosome 10 (Fig. 1). Because viral read-through transcripts
could not be detected by RT-PCR in Evi12 containing tumors
using primers in the viral LTR and the first exon of Grp94 (Valk
et al., 1999), we designed primer sets in the more 3′ coding
areas of Grp94. RT-PCR was performed on cDNA from
NFS107 and the control cell line DA28 that has no VIS in
Evi12. Several products were amplified from NFS107, which
were not detected in DA28 (shown for a PCR using exon 18
primers in Fig. 2A). The wildtype Grp94 product could
however be amplified from both cell lines after one round of
amplification (Fig. 2A). All PCR products, both from NFS107
and DA28, were cloned and sequenced. While all putative LTR-
GRP94 products from the control cell line DA28 were non-
specific, in total 16 different specific products were identified
from NFS107 using the LTR primers (Fig. 3, Supplementary
Fig. 1), showing that in this cell line Grp94 is a target of the
viral insertion in Evi12.
Eight of these products originated from the 5′LTR since
these contained Cas-Br-MuLV genomic sequences downstream
of the 5′LTR. In all these fusion cDNAs the normal Grp94 ATG
is deleted. Five of these cDNAs (CasBr5′LTR-Grp94 n107_4 to
8) include viral non-coding sequences that are located
immediately 3′ of the 5′LTR, and C-terminal parts of Grp94.
Three of the products (CasBr5′LTR-Grp94 n107_1 to 3) contain
coding sequences of the viral gag gene including the gagFig. 1. Overview of the area encompassing the common VIS Evi12 that is defined by
and orientation of the insertions (s3_x038/025, s5_178b) that were identified in a mo
upstream from the first exon of Grp94, and is located within the non-coding region of
is also a putative Evi12 target (van den Akker et al., 2005). Grp94 and Gnn consist o
Grp94 and first three exons of Gnn, are depicted in this figure. Splicing using the spl
the Grp94 exon 2 splice acceptor site (both underlined) results in fusion of the 3′LTR a
indicated at the top. The locations of the primers used for RT-PCR are shown in Figinitiation codon. The latter two of these are out of frame, but
product CasBr5′LTR-Grp94 n107_1, has an in frame fusion of
the gag and Grp94 open reading frames and includes the
Grp94 peptide binding motif (Fig. 3, Supplementary Fig. 1).
This product is a partial product since it was amplified with
primers in exon 16/15 of Grp94. We performed additional RT-
PCRs with primers immediately upstream of the gag initiation
codon and in exon 18 of Grp94 and identified three full-length
Gag-Grp94 in frame fusions. CasBrGag-Grp94 n107_1
encodes for a protein that contains amino acids 1–158 of gag
fused in frame to the extreme C-terminus of Grp94 (amino acids
785–802) that includes the KDEL sequence. CasBrGag-Grp94
n107_2 contains amino acids 1–82 of gag fused to amino acids
749–802 of Grp94. The longest product CasBrGag-Grp94
n107_3 is a fusion between gag amino acids 1–142 and Grp94
amino acids 617–802, and includes the Grp94 C-terminal
peptide binding (amino acids 624–630) (Linderoth et al., 2000)
and dimerization sites (amino acids 697–741) (Wearsch and
Nicchitta, 1996).
Surprisingly, the other eight cDNA products CasBr3′LTR-
Grp94 n107_1 to 8 originated from the 3′LTR, with the 3′ end
of the LTR directly fused to the second exon of Grp94 (Fig. 3,
Supplementary Fig. 1). The formation of these products can be
explained by the fact that the 3′LTR of the viral insertion in
NFS107 is located directly 5′ of a splice donor site in the mouse
genomic DNA that causes the removal of Grp94 exon 1 and the
normal translation initiation site of Grp94 in all products (Fig.
1). All 3′LTR products start with a short cistronic sequence,
which may influence possible translation from one of the 18
downstream ATGs that are in frame with the Grp94 ORF
(Calkhoven et al., 2003). Assuming that translation could take
place, these products could encode for N-terminally truncatedthe most 5′ and 3′ virus integrations found in NFS107 and CSL16. The position
use lymphoma model (Suzuki et al., 2002) are also indicated. Evi12 lies 0.5 kb
a novel gene Gnn (Grp94 neighboring gene) that we recently identified and that
f 18 and 31 exons, respectively. For reasons of clarity only the first two exons of
ice donor (SD) site in NFS107 immediately 3′ of the viral insertion in Evi12 and
nd Grp94 exon 2 and presence of a cistronic sequence (underlined) in the mRNA
. 3. Complete products containing this fusion are also shown in Fig. 3.
Fig. 2. (A) RT-PCR showing amplicons from cDNAs from the Cas-Br-MuLV
induced cell lines NFS107 (Evi12 positive) and DA28 (Evi12 negative) using
primer sets in respectively the viral LTR and exon 18 (upper panel) and Grp94
exons 1 and 18 (lower panel). 1 and 2 indicate first and nested PCR reactions.
Wildtype Grp94 is amplified in the first reaction from both cell lines (lower
panel). Although a few (non-specific) products are visible for the viral–Grp94
fusion in DA28, various specific cDNAs are present in NFS107 after the nested
reaction. (B–C) RT-PCR (nested reactions) performed on a panel of cDNAs
from tumor cell lines (B) and Cas-Br-MuLV induced tumors (C) using primers in
the viral LTR and exon 18 of Grp94. Several viral–Grp94 fusion products were
amplified from the NFS107 cDNA libraries. Moreover, a single specific and
identical product (see text) was amplified in two other tumors, i.e., in NFS22 and
CSL220.
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and charged region. Possibly also products are formed that have
a normal N-terminus but that due to aberrant splicing in
products CasBr3′LTR-Grp94 n107_3 to 8 (Fig. 3) show a large
C-terminal truncation or a large deletion that includes most of
the charged area and C-terminus.
Grp94 is a common viral target gene
To investigate whether generation of these products was
unique to NFS107, we screened a panel of 43 cDNAs from Cas-
Br-MuLV derived tumors or tumor cell lines for the presence of
LTR/Grp94 fusion products. A similar specific cDNA product
CasBr5′LTR-Grp94 n22/csl220 originating from the 5′LTR was
amplified in two tumors, NFS22 and CSL220 (Figs. 2B–C, 3,
Supplementary Fig. 1). Viral integrations in Evi12 have not been
identified so far in these tumors suggesting that they contain a
VIS downstream of Evi12 and upstream of exon 13 in theGrp94genomic sequence. Recently viral insertions in Evi12 were
identified in the AKXD B- and T-cell lymphoma model. We
screened two B-cell tumors from AKXD mice containing a VIS
in Evi12. From one of the tumors, S3-x025a, we were able to
amplify four viral–Grp94 fusion products AKXD5′LTR Grp94
S025 1–4 (Fig. 3, Supplementary Fig. 1). Together these results
show that Grp94 is a common viral target gene in two different
virally induced leukemia/lymphoma models.
Gag-Grp94 fusion products localize to the plasma membrane
Grp94 has been demonstrated to have a cytosolic localiza-
tion (Csermely et al., 1998; Richter and Buchner, 2001). It was
recently demonstrated that a myristylated, membrane-bound
splice variant of Hsp90, a homologue of Grp94, has oncogenic
properties (Grammatikakis et al., 2002). Interestingly, the gag
sequence in our gag/Grp94 fusions contains a N-myristylation
sequence. Therefore, we generated fusions between the three
full-length gag-Grp94 fusion cDNAs CasBrGag-Grp94 n107_1
to 3 and eGFP and studied their localization in phoenix cells.
Gag/Grp94 fusion products were present at the plasma
membrane (Fig. 4), suggesting that the myristylation sequence
targets these products to the plasma membrane.
Discussion
Hsp90 is a cytosolic chaperone protein involved in folding
and activation of substrates that include signaling molecules and
transcription factors. Hsp90 homologues are residing in the
mitochondria (Trap1) and in the ER (Grp94). Grp94 is a
glycoprotein that is 50% conserved with Hsp90 and has a
similar build-up of domains, i.e., an ATP/ADP binding pocket
containing N-terminus, followed by a negatively charged area, a
less conserved middle region and a C-terminus including
peptide binding and dimerization motifs. Binding of ATP to the
binding pocket and its subsequent conversion to ADP can
induce conformational changes that may influence Hsp90
activity and target protein (Csermely et al., 1998; Richter and
Buchner, 2001). Grp94 is believed to be involved in ER quality
control of nascent proteins and in protection of the cell to
cellular stress, i.e., hypoxia, changes in calcium or glucose
level, and low pH. Moreover, Grp94 can prevent apoptosis and
can bind and present malfolded proteins to the proteolytic
machinery. Signal sequences at the 5′ and 3′ end of Grp94 are
important for its ER localization. Increased Grp94 expression is
found in a variety in tumors, for instance in breast cancer and
multiple myeloma in humans. It has been reported that some
tumors show enhanced expression of Grp94 at the plasma
membrane (Altmeyer et al., 1996). Membrane-associated Grp94
has been shown to bind and stabilizes p185erb2, a tyrosine
kinase-receptor overexpressed in various tumors and associated
with poor prognosis (Chavany et al., 1996).
We found fusion cDNAs between Cas-Br-MuLV and Grp94
sequences in four independent tumors from two different
leukemia/lymphoma models showing that Grp94 is a common
viral target gene. We previously observed increased expression
of a novel gene, Gnn, in NFS107 due to the viral integration in
230 E. van den Akker et al. / Virology 366 (2007) 227–233Evi12. These results implicate that the effects of a single VIS on
gene expression may be very complex and involve the (in)
activation of more than one gene located near the locus.Although any of the aberrant cDNAs found to be expressed
in NFS107 may encode products that could contribute to
transformation, the myristylated gag-Grp94 fusions amplified in
Fig. 4. Aberrant Grp94 proteins are located at the plasma membrane. (A–C) CSLM pictures of HEK-293 cells transfected with full-length gagGrp94 fusion
products containing a C-terminal fusion to GFP. (A) PLNCX-GFP, (B) PLNCX-CasBrGag-Grp94 n107_1-GFP, (C) PLNCX-CasBrGag-Grp94 n107_3-GFP. (D)
PLNCX-CasBrGag-Grp94 n107_3 with internal GFP fusion is also located at the plasma membrane showing that the position of the GFP-tag does not influence the
localization.
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Hsp90n, a N-terminally truncated oncogenic form of Hsp90 that
localizes at the plasma membrane (Grammatikakis et al., 2002).
Hsp90n is highly expressed in pancreatic carcinomas and is able
to induce, at low levels of expression, neoplastic transformation
in fibroblasts and Ras-deficient adipocytes, by recruiting Raf to
the plasma membrane via its chaperone site in the C-terminus,
thereby activating downstream signaling pathways (Gramma-
tikakis et al., 2002). Like Hsp90n the CasBrGag-Grp94 n107_1,
CasBrGag-Grp94 n107_2 and CasBrGag-Grp94 n107_3 fusion
proteins have an N-terminal myristyl group and lack the normal
N-terminal ATPase domain. Moreover, CasBrGag-Grp94
n107_3 contains like Hsp90n the C-terminal chaperone binding
and dimerization motifs. Furthermore, these proteins lack
similar to Hsp90N the normal N-terminal ATPase domain but
still contain the C-terminal chaperone binding and dimerization
motifs. Myristylation has been shown previously to play an
important role in the oncogenic capacity of the viral oncogene
v-akt (Ahmed et al., 1993).
Acute myeloid leukemia is frequently the result of a
combination of genetic defects leading to altered proliferation,
differentiation and survival of immature blasts that accumulate
in the bone marrow and blood. We previously applied an in vitro
model system, 32D-G-CSFR to investigate the effects of
putative oncogenes on neutrophilic development (Jorda et al.,
2002, 2003; Morishita et al., 1992). In contrast to results
obtained with other oncogenes identified by proviral insertion,Fig. 3. Overview of aberrant viral–Grp94 fusion products. (A) Grp94 protein struct
protein domains are encoded by the underlying exons (black boxes). Like all Hsp9
followed by a charged region, a middle region and C-terminal domain with chapero
located in exon 1 and exon 18, respectively. The approximate position of the prim
indicated. Potential in frame downstream translation initiation sites are indicated by
chaperone site. Dim=dimerization motif, GPE=viral genomic region encoding Gag-
The (partial) exons contained in each product and the primer sets used for amplificati
boxes viral non-coding sequences, black boxes viral gag coding sequences or Grp94 c
ATG for some products originating from the 5′LTR or one of the downstream ATGs i
gag coding sequences. Of these partial products only 5′LTR-Grp94 n107_1 contain
products originating from the 5′LTR (5′LTR-Grp94 n107_4 to 8), may encode for p
non-coding sequences with either exon 13, 14 or 16 of Grp94. Using primers upstrea
Grp94 fusion products were amplified. Two of the products, Gag-Grp94 n107_1 and
Gag-Grp94-n107_3 contains a longer part of the Grp94 C-terminus including the p
upstream fusion compared to the partial product 5′LTR-Grp94 n107_1. Products origi
first Grp94 exon (see also Fig. 1). The product identified in NFS22/CSL220 and one.g., Evi1 or Cb2, we could not find an effect of myristylated
gag-Grp94 fusion on neutrophilic development in this model
(data not shown). This suggests a different role of this unique
fusion gene, which requires another, possibly in vivo assay to
study its role in leukemogenesis. Although the oncogenic
potential of the myristylated forms of Grp94 needs to be further
proven our results reveal a potentially important mechanism for
retroviral insertional mutagenesis, i.e., that viral insertion may
activate oncogenes by generation of fusion products with an
altered localization.
Materials and methods
RT-PCR and cloning of viral–Grp94 fusion products
RNA was isolated from cell lines and tumors using Trizol
reagent (Invitrogen). For the NFS107 and DA28 cell lines 5′-
RACE cDNA was generated using the SMART RACE cDNA
amplification kit (Clontech). RT-PCR reactions were per-
formed on the 5′-RACE cDNA with viral LTR primers in
combination with three sets of Grp94 specific primers. First
reactions were performed with primer LTR1 (5′-GGTC-
TCCTCAGAGTGATT) in combination with primers Grp94-
exon18.1 (5′-AAACCACTTCTTCCTGTGAC), Grp94-exon15.1
(5′-ATCTTCATCTTCCTTAATCC) or Grp94-exon12.1 (5′-TAC-
TTCTCATCAGCAATCTT), followed by nested reactions using
primer LTR2 (5′-GTGATTGACTACCCGCCT) and primersure and viral and Grp94 genomic structure (not on scale). The different Grp94
0 family proteins the Grp94 N-terminus contains an ATPase domain which is
ne and dimerization motifs. Grp94 has 18 exons with the start and stop codons
er sets in the viral 5′ and 3′LTR and Grp94 (arrowheads) used for RT-PCR is
the vertical lines on top of the exons. SS=signal sequence, P=peptide binding/
Pol-Env. (B) Overview of aberrant products originating from the 5′ and 3′LTR.
on are indicated. For each product grey boxes indicate the LTR sequence, white
oding sequences. The first possible translation initiation codon is either the viral
n Grp94 for all other products. Products 5′LTR-Grp94 n107_1 to 3 contain viral
s an in frame fusion of gag and Grp94 N-terminal sequences. The five other
roducts with a large N-terminal truncation. These products show fusion of viral
m of the gag ATG (black arrowheads) three additional full length in frame gag-
Gag-Grp94 n107_2 only contain the extreme Grp94 C-terminus, while product
eptide binding and dimerization motifs. This product contains a slightly more
nating from the 3′LTR promoter start with a short cistronic sequence and lack the
e of the products identified in the AKXD tumor are also shown.
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Grp94-exon15.2 (5′-CCGCAACATGTCTCTGAT) or Grp94-
exon12.2 (5′-ATCATGTCCAGAGTTTTTCG), respectively.
Reactions were performed both with Taq and Expand poly-
merase. Conditions with Taq were 5 min, 94 °C (1 cycle); 1 min,
94 °C; 1 min, 54 °C; 3 min, 72° (30 cycles); 3 min, 72 °C (1
cycle). Conditions with Expand were 5 min, 94 °C (1 cycle);
15 s, 94 °C; 39 s, 54 °C; 3 min, 72 °C (10 cycles); 15 s, 94 °C;
30 s; 54 °C; 3 min, 72 °C (20 cycles, plus 5 s, extra elongation
time added each cycle); 7 min, 72 °C (1 cycle). Wildtype Grp94
was amplified from DA28 and NFS107 cDNA using Expand
with primers Grp94-exon1.1 (5′-GAGGTGTG AGGAGCTTA-
GAC) and Grp94-exon18.1. To amplify Gag-Grp94 fusion
products from the 5′-RACE cDNA of NFS107 first reactions
were performed using Expand with primer Gag1 (5′-
TTGGCTGTTTTTCTGTATTG) and Grp94-exon18.1 followed
by primer Gag2 (5′-AAATATGGGCCAGACTGTTA) and
Grp94-exon18.2. To screen the other tumors and tumor cell
lines for generation of viral–Grp94 fusion products cDNAwas
generated using SuperScript and random hexamer primers
(Invitrogen) followed by RT-PCR with Taq polymerase, using
the above described LTR and Grp94-exon18 primers and
conditions. All PCR products were purified using MinElute
Spin Columns (Qiagen), cloned in the TA vector (Invitrogen)
and sequenced using an ABI 3100 sequencer (Perkin Elmer,
Nieuwerkerk a/d IJssel, The Netherlands) with M13 forward,
M13 reverse, LTR- and Grp94-specific primers. The complete
sequences of all products are shown in Supplementary Fig. 1.
Generation of expression constructs
To convert the Gag translation initiation sequence into an
optimal Kozak sequence the three full-length Gag-grp94 fusion
products in TA (CasBrGag-Grp94 n107_1 to 3) were amplified
by PCR using primers kgag (5′-GCCACCATGGGCCA-
GACTGTTA) and Grp94-exon18.2, cloned in the TA vector
and sequenced. After excision from the TA vector by digestion
with EcoRI, the products were blunted and inserted into StuI
digested PLNCX. To generate expression constructs containing
GFP-tagged Gag-grp94 fusion products with a Kozak sequence
the Gag-Grp94 inserts were amplified using primers kgag and
Grp94-exon18.EcoRI (5′-GAATTCATCCTTCTCTGTAGA),
cloned in TA and sequenced. Subsequently the inserts were
excised with EcoRI, filled in with klenow and inserted into
SmaI digested eGFP-N3. The C-terminally GFP-tagged Gag-
Grp94 fusions were subsequently excised by digestion with
SalI and NotI and inserted into XhoI and NotI digested
PLNCX2. To generate a Gag-Grp94 product with an internal
GFP fusion eGFP-C3 (Clontech) was cut with NheI and SmaI
and 3′ overhangs were filled in with klenow. The GFP fragment
was inserted into PLNCX-CasBrGag-Grp94 n107_3 after di-
gestion with BlnI and blunting of overhangs.
Transfection and Immunofluorescence
HEK-293 cells were grown on glass cover slips and
transfected with GFP-tagged expression constructs using thecalcium phosphate transfection method. Two days after trans-
fection cells were fixed with 4% paraformaldehyde in PBS at
4 °C for 20 min. Fixed cells were washed 3 times with PBS,
embedded in Vectashield (Vector Laboratories, Burlingame,
CA) and observed with confocal laser scanning microscopy
(CLSM).
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